SCHEMBL221445

SCHEMBL221445

O=C(O)c1cc(F)ccc1Br

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.59
CES2 O00748 2/20 0.48
CES1 P23141 2/20 0.48
PKM P14618 1/20 0.44
HSD17B10 Q99714 2/20 0.44
ANO1 Q5XXA6 1/20 0.43
LCK P06239 1/20 0.42
FYN P06241 1/20 0.42
F2R P25116 1/20 0.42
KDM4E B2RXH2 3/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
ALDH1A1 P00352 2/20 0.42
TTR P02766 2/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
DHFR P00374 1/20 0.42
LMNA P02545 1/20 0.42
ALB P02768 1/20 0.42
HMGB1 P09429 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9000270 0.98 KEAP1 (0.57) KEAP1CES2CES1PKMHSD17B10
Hydrochloric Acid SCHEMBL1372131 0.98 KEAP1 (0.57) KEAP1CES2CES1PKMHSD17B10
SCHEMBL29280607 0.83 CES2 (0.50) KEAP1CES2CES1PKMANO1
SCHEMBL111637 0.83 KEAP1 (0.53) KEAP1CES2CES1PKMHSD17B10
SCHEMBL2523960 0.81 DGAT1 (0.50) KEAP1CES2CES1PKMANO1
SCHEMBL4649267 0.81 CES2 (0.47) KEAP1CES2CES1PKMANO1
SCHEMBL31315010 0.81 CES2 (0.47) KEAP1CES2CES1PKMANO1
SCHEMBL29847023 0.81 F2R (0.48) KEAP1CES2CES1PKMANO1
SCHEMBL485712 0.81 F2R (0.48) KEAP1CES2CES1PKMANO1
SCHEMBL336978 0.79 KEAP1 (0.65) KEAP1CES2CES1HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119569654-A 9-Aminoacridine compound with multi-electron-withdrawing substituent, and preparation method and application thereof 郑州大学 2025-03-07 CN claimed
CN-119285635-A Synthesis of 8H-indolo [3,2,1-DE ] phenanthridine-8-ketone compound from carbazole and o-bromobenzoic acid and synthesis method thereof 陕西科技大学 2025-01-10 CN claimed
CN-118955276-A Preparation method of 2-bromo-5-hydroxybenzoic acid 舞阳威森生物医药有限公司 2024-11-15 CN claimed
CN-117756766-A 3-hydroxy-8-fluoro-6H-benzo [ c ] chromen-6-one derivative, and preparation method and application thereof 常州大学 2024-03-26 CN claimed
CN-116396159-A Synthesis method of 2,2' -biphenyl dicarboxylic acid compound 湖南大学 2023-07-07 CN claimed
CN-1328996-A Preparation of 2,4-dibromo-5-fluorobenzonitrile and 2,4-dibromo-5-fluorobenzoic acid by using ammonia oxidation process UNIV WUHAN (CN) 2002-01-02 CN claimed
EP-0647614-B1 Process for the préparation of 5-fluoro anthranilic acid HOECHST AG (DE) 1997-06-04 EP claimed
US-5523472-A Process for the preparation of 5-fluoroanthranilic acid HOECHST AKTIENGESELLSCHAFT (DE) 1996-06-04 US claimed
EP-0647614-A1 Process for the préparation of 5-fluoro anthranilic acid HOECHST AKTIENGESELLSCHAFT (DE) 1995-04-12 EP claimed
JP-7165687-A None JP disclosed
CN-117164587-B Ester group-containing substituted evodiamine derivative, preparation method and application 南华大学附属第一医院 2026-05-12 CN disclosed
US-20260116868-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-04-30 US disclosed
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2026-04-21 US disclosed
US-20260085070-A1 HETEROCYCLIC CBL-B INHIBITORS FOR THE TREATMENT OF CANCER HOTSPOT THERAPEUTICS INC (US) 2026-03-26 US disclosed
JP-H07165687-A PREPARATION OF 5-FLUOROANTHRANILIC ACID HOECHST AG 1995-06-27 JP disclosed
WO-1995016682-A1 CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS ZENECA LIMITED (GB) 1995-06-22 WO disclosed
EP-0647614-A1 Process for the préparation of 5-fluoro anthranilic acid HOECHST AKTIENGESELLSCHAFT (DE) 1995-04-12 EP disclosed
EP-0647614-A1 Process for the préparation of 5-fluoro anthranilic acid HOECHST AKTIENGESELLSCHAFT (DE) 1995-04-12 EP disclosed
US-3987186-A ANTIALLERGENS BOEHRINGER INGELHEIM GMBH (DT) 1976-10-19 US disclosed
US-3953595-A Substituted benzoic acid hypolipemic agents PFIZER INC. (US) 1976-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085070-A1 HETEROCYCLIC CBL-B INHIBITORS FOR THE TREATMENT OF CANCER CBL, CBLB, CBLC KEAP1 964/4885CES2 2022/4885CES1 304/4885
US-20260116868-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF CBLB, CBLC, CBL KEAP1 358/4885CES2 1088/4885CES1 148/4885
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives NR3C2, NR5A1, SRD5A2 KEAP1 2573/4885CES2 526/4885CES1 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.